Neuronetics Showcases Commitment to Mental Health Innovation
MALVERN, Pa. — Neuronetics, Inc. (NASDAQ: STIM), a pioneering company in medical technology focused on mental health care, is taking bold steps to enhance patient outcomes through innovation. With a steadfast commitment to making mental health care accessible, Neuronetics is excited to announce significant developments during the 13th Annual Clinical TMS Society Meeting.
Participation in the 2025 Clinical TMS Society Annual Meeting
Taking place in San Diego, California, this prestigious event from June 11–14 is an excellent platform for sharing groundbreaking research and advancements in Transcranial Magnetic Stimulation (TMS). As a Silver Sponsor, Neuronetics is ready to present key findings from their extensive TrakStar dataset, recognized as the largest outcomes database in TMS therapy.
Among the insights revealed is a retrospective analysis comparing clinical outcomes for patients treated with the innovative Figure-8 coil by NeuroStar versus Brainsway’s H-coil. This comparison, derived from Greenbrook’s multi-site study, aims to shed light on device-specific performance and efficacy in treating depression.
Key Presentations Highlighting Real-World Effectiveness
At this pivotal meeting, NeuroStar will present important findings focused on treating late-life depression and comparing different TMS devices:
Age is Just a Number: Real-world Effectiveness of TMS in Late-Life Depression
- Presenter: Dr. Eleanor Cole, Senior Director of Clinical Innovation
- Overview: The presentation will cover a significant analysis of elderly adults (70 years and older) diagnosed with Major Depressive Disorder (MDD) and treated using TMS technology.
- Presentation Date: June 13 at 4:00 PM PDT
Clinical Outcomes in Patients Treated with NeuroStar and Brainsway TMS Therapy Devices
- Presenter: Cory Anderson, Chief Technology Officer
- Overview: This analysis includes data from 200 Greenbrook centers evaluating the real-world efficacy of TMS therapy across devices.
- Presentation Date: June 13 at 4:00 PM PDT
Advancements in Personalized Care Trial Program
In conjunction with these presentations, Greenbrook Mental Wellness Centers is excited to roll out a personalized care trial program. This initiative aims to utilize qEEG-informed protocols for administering TMS therapy via the NeuroStar TMS System. Initial findings suggest this personalized approach shows promise in treatment delivery, with further details expected to be shared soon.
As Cory Anderson remarked, “Our research efforts signify NeuroStar's dedication to leading the way in psychiatric care and optimizing TMS efficacy for diverse populations.”
Exploring NeuroStar TMS Therapy
Neuronetics continues to mark its presence in the healthcare landscape as a trusted provider of mental health treatments. The NeuroStar Advanced Therapy is a non-invasive, drug-free solution for individuals experiencing serious mental health challenges, particularly when traditional medications have fallen short. The treatment boasts a remarkable safety profile and effectiveness record, having facilitated over 7.4 million treatments to date.
In addition, Greenbrook treatment centers, operating under Neuronetics, provide comprehensive TMS therapy as part of a multi-faceted approach to addressing MDD and other disorders. They also offer innovative treatments, including SPRAVATO (esketamine) Nasal Spray, for individuals facing treatment-resistant depression (TRD).
Safety and Regulatory Information
The NeuroStar Advanced Therapy System, cleared by the U.S. Food and Drug Administration, is indicated as an adjunct for adult patients with comorbid anxiety symptoms and also extends to adolescents aged 15-21. For more details on safety and proper use, medical professionals and patients can refer to the NeuroStar website.
Connecting with Neuronetics
As Neuronetics leads the charge in mental health innovation, they strongly encourage engagement from medical professionals, investors, and media representatives. For further information regarding their groundbreaking NeuroStar TMS Therapy, contacting their team is highly recommended.
Neuronetics Contact:
Investors:
Mike Vallie or Mark Klausner
ICR Healthcare
443-213-0499
ir@neuronetics.com
Media:
EvolveMKD
646.517.4220
NeuroStar@evolvemkd.com
Frequently Asked Questions
What is the main focus of Neuronetics as a company?
Neuronetics is dedicated to advancing mental health care through innovative technologies, particularly TMS therapy.
What are the highlights from the recent TMS Society Meeting?
Key presentations focused on the effectiveness of TMS in treating elderly patients and comparing different TMS devices.
What is the NeuroStar Advanced Therapy?
It is a non-invasive treatment designed to help individuals with depression, especially when other treatments have failed.
How does Neuronetics ensure safety in their treatments?
The NeuroStar Advanced Therapy System is FDA-cleared, ensuring its safety and efficacy in treating various mental health conditions.
Where can I find more information about NeuroStar services?
Detailed information can be obtained from their official website, which outlines services, research, and treatment options.
